NCT02047604 - (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 23, 2017

Study Completion Date

March 23, 2017

Conditions

Rheumatoid Arthritis

Interventions

DRUG

SAN-300 0.5 mg/kg QW

DRUG

SAN-300 1.0 mg/kg QW

DRUG

SAN-300 2.0 mg/kg QOW

DRUG

SAN-300 4.0 mg/kg QOW

DRUG

SAN-300 4.0 mg/kg QW

DRUG

Placebo

Trial Locations (12)

11201

Santarus Clinical Investigational Site 1009, Brooklyn

27599

Santarus Clinical Investigational Site 1019, Chapel Hill

28144

Santarus Clinical Investigational Site 1006, Salisbury

28210

Santarus Clinical Investigational Site 1014, Charlotte

33511

Santarus Clinical Investigational Site 1013, Brandon

34684

Santarus Clinical Investigational Site 1003, Palm Harbor

44130

Santarus Clinical Investigational Site 1001, Middleburg Heights

63031

Santarus Clinical Investigational Site 1017, Florissant

85023

Santarus Clinical Investigational Site 1012, Phoenix

90048

Santarus Clinical Investigational Site 1008, Los Angeles

92020

Santarus Clinical Investigational Site 1004, El Cajon

94578

Santarus Clinical Investigational Site 1011, San Leandro

All Listed Sponsors

lead

Bausch Health Americas, Inc.

INDUSTRY